Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01961297

Enrollment

Registered

2013-10-11

Start date

2012-07-31

Completion date

2017-06-30

Last updated

2017-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spasmodic Dysphonia, Voice Tremor

Keywords

dystonia, tremor, treatment, sodium oxybate, brain activity

Brief summary

The proposed research aims to determine brain abnormalities in patients with spasmodic dysphonia (SD) and voice tremor (VT) as the basis for characterization of central mechanisms underlying symptom improvement following the use of sodium oxybate, a novel oral medication for the treatment of ethanol-responsive dystonia. The proposed research is relevant to public health because the elucidation of disorder-specific mechanistic aspects of brain organization in SD vs. SD/VT is ultimately expected to lead to establishment of enhanced criteria for clinical management of these disorders, including differential diagnosis and treatment. Thus, the proposed research is relevant to the part of NIH's mission that pertains to developing fundamental knowledge that will help to reduce the burdens of human disability.

Detailed description

Spasmodic dysphonia (SD) is a chronic debilitating condition, characterized by selective loss of voluntary voice control during speech production due to uncontrolled spasms in the laryngeal muscles. SD becomes even more incapacitating when it is associated with action-induced voice tremor (VT) due to its poor response to gold standard treatment with botulinum toxin. There is, therefore, a critical need to identify new treatment opportunities for SD/VT patients who receive limited, if any, benefits from botulinum toxin injections. The design and use of novel therapeutic approaches for these patients will, however, be largely unattainable if the central mechanisms of SD and VT development remain unknown. Our long-term goal is to determine the pathophysiology of SD and related disorders, such as VT, for the development of new diagnostic and treatment options for these patients. The objective of this application is to identify brain abnormalities in SD and SD/VT patients as the basis for characterization of central mechanisms underlying symptom improvement following the use of sodium oxybate, a novel pharmacological agent for treatment of ethanol-responsive dystonia. Our central hypothesis is that, compared to SD patients, SD/VT patients will have additional brain abnormalities within the sensorimotor brain circuits controlling voice production, which are being modulated to a greater extent with sodium oxybate treatment. We further postulate that clinical efficacy of sodium oxybate treatment will correlate with its central modulatory effects. The rationale for the proposed research is that identification of distinct brain mechanisms underlying SD and SD/VT clinical manifestations would provide the necessary insights into the pathophysiology of these disorders, while understanding the neural correlates of sodium oxybate action would allow establishment of a scientific rationale for the use of a novel treatment in these disorders. Using a comprehensive approach of multi-modal neuroimaging and clinico-behavioral testing, our central hypothesis will be tested by pursuing two specific aims: (1) determine disorder-specific brain abnormalities in SD and SD/VT patients, and (2) characterize the central effects of sodium oxybate treatment in ethanol-responsive SD and SD/VT patients. This research is innovative because it focuses not only on identification of distinct pathophysiological factors contributing to SD and VT development, but also on discovery of mechanisms of central effects of a novel oral medication, sodium oxybate, which holds promise for treatment of refractory symptoms in SD and SD/VT. The proposed research is significant because it will advance our understanding of the pathophysiology of dystonia in general and SD in particular as well as will have direct impact on improvement of clinical management of SD and SD/VT patients.

Interventions

DRUGSodium oxybate

Sodium oxybate

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinically documented diagnosis of SD and/or VT with positive effects of alcohol on their symptoms; * Age from 21 to 80 years; * Native English speakers; * Right-handedness (based on Edinburgh Handedness Inventory).

Exclusion criteria

* Subjects who are incapable of giving an informed consent; * Pregnant and breastfeeding women until a time when they are no longer pregnant or breastfeeding will be excluded from the study. All patients of childbearing potential will be required to agree to use a reliable method of contraception prior and during the treatment with sodium oxybate and prior to receiving botulinum toxin. The method of contraception will be documented in the patient's research chart. All women of childbearing potential will undergo a urine pregnancy test, which must be negative for study participation; * Subjects with past or present medical history of 1. any neurological disorders, except for spasmodic dysphonia and voice tremor, will be excluded from the study in order to maintain the homogenous patient population, allow for the evaluation of drug effect on CNS without confounding by the presence of other neurological conditions, and identify SD and VT disorder-specific changes in brain function and structure. Patients who report other past or present neurological problems, such as stroke, movement disorders other than SD and VT, brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence will be excluded. As voice tremor is one of the forms of essential tremor, patients with moderate to severe essential tremor affecting other body parts will be excluded from the study. All patients who have dystonic movements in other than larynx body regions will also be excluded from the study; 2. psychiatric problems, such as schizophrenia, major and/or bipolar depression, obsessive-compulsive disorder, will be excluded to maintain the homogenous patient population, allow for the evaluation of drug effect on CNS without confounding by the presence of psychiatric conditions and identify disorder-specific changes in brain function and structure; 3. laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis; 4. known past or present history of grade 2 or higher hepatic and renal dysfunction according to the NCI criteria.; 5. known past or present history of moderate to severe congestive heart failure; 6. known past or present history of cognitive impairment and active suicidal ideations; * Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles. The duration of positive effects of botulinum toxin vary from patient to patient but lasts on average for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic prior to the entering the study, except the substudy, which will examine the effects of combined botulinum toxin and sodium oxybate treatments on abnormal brain function in SD and VT patients; * To avoid the possibility of confounding effects of drugs acting upon the central nervous system, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial intake screening. Those patients who receive medication(s) affecting the central nervous system (except sodium oxybate) will be excluded from the study. * The participants will be asked whether they have undergone any head and neck surgeries, particularly any brain surgery and laryngeal surgeries, such as thyroplasty, laryngeal denervation, and selective laryngeal adductor denervation-reinnervation. Because both brain and laryngeal surgery may potentially lead to the brain structure and function re-organization, all subjects with history of brain and/or laryngeal surgery will be excluded from the study. * The subjects who have tattoos, ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that cannot be removed for the purpose of MRI study participation.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants Who Reported Positive Effects.	Day 1	Number of participants who had reported positive effects of at least one alcohol drink on their voice symptoms

Secondary

Measure	Time frame	Description
Number of Voice Breaks	baseline and Day 1	The number of SD-characteristic voice breaks in each sentence at pre-drug and post-drug assessment
Voice Harshness Severity	baseline and Day 1	Visual analog scale of severity (0 for none, 100 for most severe/profound)
Breathlessness Severity	baseline and Day 1	Visual analog scale of severity (0 for none, 100 for most severe/profound)
Voice Tremor Severity	baseline and Day 1	Visual analog scale of severity (0 for none, 100 for most severe/profound)

Countries

United States

Participant flow

Recruitment details

75 subjects were consented, some did not meet criteria, and 53 were enrolled into the study.

Participants by arm

Arm	Count
Spasmodic Dysphonia Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)	28
Spasmodic Dysphonia/Voice Tremor Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)	22
Total	50

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	unconfirmed diagnosis of SD	2	1

Baseline characteristics

Characteristic	Spasmodic Dysphonia	Total	Spasmodic Dysphonia/Voice Tremor
Age, Continuous	50.7 years STANDARD_DEVIATION 11.3	54.4 years STANDARD_DEVIATION 11.8	58.0 years STANDARD_DEVIATION 12.2
Age of onset of dysphonia	37.7 years STANDARD_DEVIATION 11	40.9 years STANDARD_DEVIATION 12.6	44.1 years STANDARD_DEVIATION 14.2
Duration of symptom of dysphonia	13.4 years STANDARD_DEVIATION 11.5	14.1 years STANDARD_DEVIATION 12.1	14.7 years STANDARD_DEVIATION 12.7
Dystonia subtype ABSD	12 Participants	12 Participants	0 Participants
Dystonia subtype ABSD/VT	0 Participants	7 Participants	7 Participants
Dystonia subtype ADSD	16 Participants	16 Participants	0 Participants
Dystonia subtype ADSD/VT	0 Participants	15 Participants	15 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	1 Participants	3 Participants	2 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	27 Participants	47 Participants	20 Participants
Sex: Female, Male Female	18 Participants	37 Participants	19 Participants
Sex: Female, Male Male	10 Participants	13 Participants	3 Participants
Spasmodic dysphonia severity	25.6 years STANDARD_DEVIATION 16.3	28.0 years STANDARD_DEVIATION 16.6	30.3 years STANDARD_DEVIATION 16.8
Voice Tremor severity	—	49.3 units on a scale STANDARD_DEVIATION 24.7	49.3 units on a scale STANDARD_DEVIATION 24.7

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 28	0 / 22
other Total, other adverse events	14 / 28	10 / 22
serious Total, serious adverse events	0 / 28	0 / 22

Arm	Measure	Group	Value (MEAN)	Dispersion
Spasmodic Dysphonia/Voice Tremor	Voice Tremor Severity	Baseline - pre treatment	51.2 units on a scale	Standard Deviation 23.6
Spasmodic Dysphonia/Voice Tremor	Voice Tremor Severity	Day 1 - post treatment	31.4 units on a scale	Standard Deviation 18.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026